Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only an introduction to drugs related to medical health, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
In 2016, Regeneron Pharmaceuticals signed a six-year agreement with Intellia Therapeutics to jointly develop, license, and commercialize novel gene therapies based on gene editing, through which Intellia earned approximately $125 million in revenue.In June 2020, Regeneron and Intellia Therapeutics announced the expansion of their collaboration to continue the joint development of gene therapies for hemophilia A and B using CRISPR/Cas9 gene editing technology. Intellia Therapeutics received a $70 million upfront payment and a $30 million equity investment.In June 2021, the in vivo CRISPR-Cas9 genome editing therapy NTLA-2001, co-developed by Intellia Therapeutics and Regeneron Pharmaceuticals, Inc., achieved positive interim data in Phase I clinical trials for the treatment of transthyretin amyloidosis (ATTR).Now,Intellia Exits Hemophilia B Program, Hands Over CRISPR/Cas9 Gene Editing Work Based on Coagulation Factor IX to Partner Regeneron。Although Intellia has exited, it still has to bear 35% of the cost and will not receive related profits. However, it is expected to obtain milestone payments of up to $320 million as well as double-digit royalties.
Intellia R&D Pipeline
An Intellia spokesperson stated that the decision to opt out only pertains to the Hemophilia B program, while work on the Hemophilia A program is continuing; andOpting out of the hemophilia B program does not affect other programs of the company., including the Phase 3 program for NTLA-2001 in the treatment of transthyretin amyloidosis led by Intellia. According to the latest reports, the first patient has been dosed in this Phase 3 trial.
About Intellia Therapeutics
Intellia Therapeutics, founded in 2014, is a gene-editing company focused on developing CRISPR/Cas9-based therapies. The company's co-founders include Nobel laureate Jennifer Doudna. In 2014, Intellia secured $15 million in Series A funding led by Atlas Venture and Novartis, followed by $70 million in Series B funding led by OrbiMed HealthCare in 2015. The company went public on NASDAQ in 2016 and currently has a market value of $2.66 billion.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc., is an American company. It was founded in 1988 by Leonard S. Schleifer, M.D., Ph.D., a neurologist and assistant professor at Cornell University Medical College, initially focusing on neurotrophic factors and their regenerative capabilities, hence the name. The company later expanded into research on cytokines and tyrosine kinase receptors.
References:
https://www.fiercebiotech.com/biotech/intellia-opts-out-hemophilia-gene-editing-work-regeneron
March 27, Beijing |Click on the image to register now ↓↓
